Needham analyst Mike Matson lowered the firm’s price target on Masimo to $136 from $207 and keeps a Buy rating on the shares. Masimo preannounced Q2 revenue that was well below consensus with both the healthcare and the non-healthcare businesses missing the firm’s estimates, the analyst tells investors in a research note. Needham believes Masimo’s healthcare challenges are mostly transitory, but that its non-healthcare challenges are longer-term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MASI: